How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,854 results for

Sweet 16 Cognitive Screening Test

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Sweet 16 Cognitive Screening Test

Sweet 16 Cognitive Screening Test Sweet 16 Cognitive Screening Test Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Sweet 16 Cognitive (...) Screening Test Sweet 16 Cognitive Screening Test Aka: Sweet 16 Cognitive Screening Test II. Criteria Three minute recall Orientation (8 items) Backward digital span III. Scoring One point for each correct item Maximum score: 16 IV. Interpretation Score <14 suggests V. Efficacy : 80% : 70% Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Sweet 16 Cognitive Screening Test." Click on the image (or right click) to open the source website

2018 FP Notebook

2. AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis

AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis Appropriate.Safe.Affordable © 2019 AIM Specialty Health 2068-0319 Clinical Appropriateness Guidelines Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis EFFECTIVE MARCH 3, 2020 PROPRIETARY Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2019 Informed Medical Decisions, Inc. All Rights Reserved. 2 Table of Contents (...) Scope 3 Appropriate Use Criteria 3 Carrier Screening for Familial Disease 3 Fragile X 3 Carrier Screening for Common and Ethnic Genetic Diseases 3 Cystic Fibrosis 3 Spinal Muscular Atrophy 4 Hemoglobinopathies 4 Ashkenazi Jewish Carrier Screening 4 Other Ethnicities 5 Carrier Screening Not Clinically Appropriate 5 Preimplantation Genetic Screening and Diagnostic Testing of Embryos 5 Preimplantation Genetic Screening for Common Aneuploidy 6 Prenatal Cell-Free DNA Screening 6 Prenatal Molecular

2020 AIM Specialty Health

3. Screening for Cognitive Impairment in Older Adults

In Username or Email * Password * Remember Me Don't have an account? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Synthesis Screening for Cognitive Impairment in Older Adults Guidelines Being Compared: Canadian Task Force on Preventive Health Care (CTFPHC) Recommendations on screening (...) is insufficient, clinicians should remain alert to early signs or symptoms of cognitive impairment (for example, problems with memory or language) and evaluate as appropriate. The National Institute on Aging has information on the detection and management of cognitive impairment for patients and clinicians, including a database of tools to detect cognitive impairment (available at ). Screening Tests Screening tests for cognitive impairment in the clinical setting generally include asking patients to perform

2017 National Guideline Clearinghouse (partial archive)

4. AIM Clinical Appropriateness Guidelines for Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis

15 Revision History 16 PROPRIETARY Guidelines developed by, and used with permission from, Informed Medical Decisions, Inc. © 2019 Informed Medical Decisions, Inc. All Rights Reserved. 3 Scope This document addresses genetic testing in the reproductive setting, including both testing of parents (carrier screening) and testing of fetal or embryonic DNA (prenatal diagnosis, preimplantation genetic testing, cell-free DNA). All tests listed in these guidelines may not require prior authorization (...) Decisions, Inc. All Rights Reserved. 16 3 Brezina PR, Anchan R, Kearns WG. Preimplantation genetic testing for aneuploidy: what technology should you use and what are the differences? J Assist Reprod Genet. 2016 Jul;33(7):823-32. Epub 2016 Jun 14. PubMed PMID: 27299602. 4 Debrock S, Melotte C, Spiessens C, et al. Preimplantation genetic screening for aneuploidy of embryos after in vitro fertilization in women aged at least 35 years: a prospective randomized trial. Fertil Steril. 2010 Feb;93(2):364-73

2019 AIM Specialty Health

5. Recommendations on screening for cognitive impairment in older adults

of mild cognitive impair- ment does not produce clinically meaningful benefit. Thus, the accuracy of potential screening tools was less important for determining an over- all recommendation, but it was still important to understand the likely burden of false-positive results if screening were to be implemented. As such, a systematic review of the evidence on diagnostic test properties was not conducted. Instead, two recent high-quality systematic reviews 11,16 (AMSTAR [A Measurement Tool to Assess (...) (AMSTAR score of 9), reported a sensitivity of 88% (95% CI 81% to 93%) and a specificity of 86% (95% CI 82% to 90%) for MMSE at cut-off scores of 23/24 or 24/25 to detect dementia. Test performance to detect mild cognitive impairment was based on a smaller body of literature. A recent meta-analysis, 16 also rated as having high methodologic quality (AMSTAR score of 10), reported pooled estimates across 108 studies (n = 36 080) of 81% sensitivity (95% CI 78% to 84%) and 89% specificity (95% CI 87

2015 CPG Infobase

6. Screening of fetal aneuploidies whereby non-invasive prenatal test (NIPT)

Screening of fetal aneuploidies whereby non-invasive prenatal test (NIPT) Dec2015 © EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged 1 EUnetHTA Joint Action 3 WP4 Version 1.5, 23 rd February 2018 Rapid assessment of other technologies using the HTA Core Model ® for Rapid Relative Effectiveness Assessment SCREENING OF FETAL TRISOMIES 21, 18 AND 13 BY NONINVASIVE PRENATAL TESTING Project ID: OTCA03 Screening of fetal trisomies 21, 18 and 13 by noninvasive (...) Cunqueiro Hospital, Spain, who had undergone NIPT participated in the draft project plan consultation phase. Screening of fetal trisomies 21, 18 and 13 by noninvasive prenatal testing Version 1.5, 23rd February 2018 EUnetHTA Joint Action 3 WP4 3 Consultation of the draft rapid assessment Manufacturers [v 1.2] (factual accuracy check) Sequenom Laboratories, San Diego, CA, USA Ariosa Diagnostics Inc./Roche Sequencing Solutions Inc., San Jose, California, USA Natera ® , San Carlos, CA, USA Premaitha Health

2018 EUnetHTA

7. Sweet 16 Cognitive Screening Test

Sweet 16 Cognitive Screening Test Sweet 16 Cognitive Screening Test Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Sweet 16 Cognitive (...) Screening Test Sweet 16 Cognitive Screening Test Aka: Sweet 16 Cognitive Screening Test II. Criteria Three minute recall Orientation (8 items) Backward digital span III. Scoring One point for each correct item Maximum score: 16 IV. Interpretation Score <14 suggests V. Efficacy : 80% : 70% Images: Related links to external sites (from Bing) These images are a random sampling from a Bing search on the term "Sweet 16 Cognitive Screening Test." Click on the image (or right click) to open the source website

2015 FP Notebook

8. Screening Tools to Identify Adults with Cognitive Impairment Associated with a Cerebrovascular Accident or Traumatic Brain Injury

with cerebrovascular accident or traumatic brain injury. Additional references of potential interest are provided in the appendix. OVERALL SUMMARY OF FINDINGS The systematic review 1 identified a lack of evidence regarding the diagnostic accuracy of tests for executive function in adults with acquired brain injury. The authors concluded that better quality evidence is needed regarding tests of executive function. 1 The 30 non-randomized studies examined various cognitive screening instruments for several different (...) impairment = 84% (N = 124) Screening Tools to Identify Adults with Cognitive Impairment Associated with a CVA or TBI 2 Table 2: Summary of Included Non-Randomized Studies Author and Year Patient Population Tests Used Findings Cog-4 Patients classified with cognitive impairment = 37% (N = 62) Sensitivity = 0.36 Specificity = 0.96 PPV = 0.98 NPV = 0.23 Redfors, 2014 4 N = 281 MMSE Patients classified with cognitive impairment = 65% BNIS Patients classified with cognitive impairment = 89% Webb, 2014 5 N

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

9. Screening Tools to Identify Adults with Cognitive Impairment Associated with Dementia

= 95.7% Specificity = 87.5% Greater accuracy than ACE and MMSE Quinn, 2014 3 10 studies; N = 2644; 379 with dementia Community setting IQCODE; threshold 3.3 Clinical diagnosis Sensitivity = 0.80 Specificity = 0.84 PLR = 5.2 NLR = 0.23 Screening Tools to Identify Adults with Cognitive Impairment Associated with Dementia 2 Table 2: Summary of Included Studies First Author and Year Patient Population Index Test(s) Comparator(s) or Reference Standard Findings Yokomizo, 2014 4 13 studies 34 cognitive (...) accuracy than MMSE. AUROC = 0.934 vs. 0.772 Screening Tools to Identify Adults with Cognitive Impairment Associated with Dementia 5 Table 2: Summary of Included Studies First Author and Year Patient Population Index Test(s) Comparator(s) or Reference Standard Findings Fuchs, 2012 26 N = 423 Visual Association Test Clinical diagnosis Sensitivity = 95.2% Specificity = 96.0% PPV = 55.6% NPV = 99.7% Mini-Cog, CDT, verbal fluency, episodic memory, and subjective complaints Mini-Cog and immediate and delayed

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

10. Screening Tools to Identify Adults with Cognitive Impairment Associated with a Neurological Impairment: Diagnostic Accuracy

Tools to Identify Adults with Cognitive Impairment Associated with a Neurological Impairment 8 PubMed: PM22763350 26. Chen R, Xiong KP, Huang JY, Lian YX, Jin F, Li ZH, et al. Neurocognitive impairment in Chinese patients with obstructive sleep apnoea hypopnoea syndrome. Respirology. 2011 Jul;16(5):842-8. PubMed: PM21507144 27. Olson RA, Iverson GL, Carolan H, Parkinson M, Brooks BL, McKenzie M. Prospective comparison of two cognitive screening tests: diagnostic accuracy and correlation (...) systematic reviews, one randomized controlled trial, and 25 non-randomized studies were identified regarding diagnostic accuracy of screening tools to identify adults with cognitive impairment associated with a neurological impairment. No health technology assessments were identified. Additional references of potential interest are provided in the appendix. OVERALL SUMMARY OF FINDINGS One systematic review 1 compared tests for cognitive impairment in patients with human immunodeficiency virus (HIV

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

11. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management

Stroke and transient ischaemic attack in over 16s: diagnosis and initial management Strok Stroke and tr e and transient ischaemic attack in ansient ischaemic attack in o ov ver 16s: diagnosis and initial er 16s: diagnosis and initial management management NICE guideline Published: 1 May 2019 www.nice.org.uk/guidance/ng128 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128) © NICE 2019. All rights reserved. Subject

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

12. Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders. (Abstract)

Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders. Considering the similarities between HIV-associated neurocognitive disorders (HAND) and neurodegenerative dementias and the frequency of executive dysfunctions among HIV-positive patients, we evaluated the accuracy of the Frontal Assessment Battery and Clock-Drawing Test together with the Three Questions Test and International HIV Dementia Scale to screen for HAND.A cross-sectional (...) monocentric study was conducted from 2010 to 2017. The index tests were represented by the four screening tools; the reference standard was represented by a comprehensive neurocognitive battery used to investigate 10 cognitive domains. Patients were screened by a trained infectious diseases physician and those showing International HIV Dementia Scale scores ≤ 10 and/or complaining of neurocognitive symptoms were then evaluated by a trained neuropsychologist.A total of 650 patients were screened and 281

2018 HIV medicine

13. Chronic obstructive pulmonary disease in over 16s: diagnosis and management

the results of a reversibility test performed on different occasions can be inconsistent and not reproducible Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 9 of 65over-reliance on a single reversibility test may be misleading unless the change in FEV1 is greater than 400 ml the definition of the magnitude of a significant change (...) obstructive pulmonary disease in over 16s: diagnosis and management (NG115) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 11 of 65exercise capacity (for example, 6-minute walk test) TLCO whether the person meets the criteria for long-term oxygen therapy and/or home non- invasive ventilation multimorbidity frailty. [2010, amended 2018] [2010, amended 2018] T o find out why the committee made the recommendations

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

14. Development and validation of a dementia screening tool for primary care in Taiwan: Brain Health Test. Full Text available with Trip Pro

Development and validation of a dementia screening tool for primary care in Taiwan: Brain Health Test. To develop a simple dementia screening tool to assist primary care physicians in identifying patients with cognitive impairment among subjects with memory complaints or at a high risk for dementia.The Brain Health Test (BHT) was developed by several experienced neurologists, psychiatrists, and clinical psychologists in the Taiwan Dementia Society. Validation of the BHT was conducted (...) in the memory clinics of various levels of hospitals in Taiwan.All dementia patients at the memory clinics who met the inclusion criteria of age greater or equal to 50 years were enrolled. Besides the BHT, the Mini-Mental State Examination and Clinical Dementia Rating were used to evaluate the cognition state of the patients and the severity of dementia.The BHT includes two parts: a risk evaluation and a cognitive test (BHT-cog). Self or informants reports of memory decline or needing help from others

2018 PLoS ONE

15. Alcohol-related trauma reinjury prevention with hospital-based screening in adult populations Full Text available with Trip Pro

or others from hazardous alcohol use behaviors. [6–8] The SBIRT begins with screening patients to identify whether a patient's use of alcohol places them and others at risk and therefore warrants a brief intervention. A number of different screening tools are available including Alcohol Use Disorders Identification Test (AUDIT), Michigan Alcoholism Screening Test, and the CAGE questionnaire which is named as an acronym for its four questions about alcohol-related behaviors and feelings (Cut down (...) mitigate reimbursement concerns associated with measuring BAC at time of admission. The Centers for Medicaid and Medicare Services, however, has recognized the merit of intervention programs and created a specific billing code to enable reimbursement. [29] One barrier to implementation may be the lack of training for surgeons concerning the various alcohol screening tools available. However, trauma surgeons can be taught the cognitive skills needed to screen patients for hazardous alcohol use

2020 Eastern Association for the Surgery of Trauma

16. Best practice to identify and prevent cognitive bias in clinical decision-making

or therapeutic errors. In terms of best practice around strategies to reduce, manage and prevent cognitive bias, the evidence body is also limited. The only intervention shown to be successful was reflection on diagnostic hypothesis. Reflection on the initial formulated diagnosis was induced by means of instructions, either at test or during training or both. The instructions were either non-specific (unguided) prompting a need to relook or re-evaluate the initial diagnostic hypothesis, or specific (...) than two-thirds of the reviewed interventions were at least partially effective. Results should however, still be interpreted with caution due to heterogeneity between included studies, and other methodological limitations. The most recent randomised controlled trial tested a de-biasing strategy during clinical cases by clinicians. The intervention was delivered via an online application and found that the use of the tool overall did not have any measurable effect on cognitive bias. Qualitative

2019 Monash Health Evidence Reviews

17. Mass deworming for improving health and cognition of children in endemic helminth areas: A systematic review and individual participant data network meta?analysis Full Text available with Trip Pro

for schistosomiasis (praziquantel, metrifonate, hycanthone) with or without micronutrients or food. 4.1.4 Types of outcome measures The primary health outcomes were change from baseline in: weight (kg), height (cm), plasma ferritin, cognition and haemoglobin (g/L). We included studies which measured weight, haemoglobin, plasma ferritin, cognition or height. Cognition could be measured using scales that measured development (e.g., Raven's matrices) or tests that assessed attention using digit recall. We did (...) such as the World Bank, World Food Program and International Food Policy Research Institute, as per the prior Campbell review (Welch et al., ). We also contacted authors of studies and members of our advisory board for any unpublished studies or grey literature reporting eligible studies. We checked reference lists of relevant studies and reviews. Titles and abstracts were screened in duplicate by two reviewers. We pilot‐tested the screening criteria at both title and abstract screening stage and full text

2019 Campbell Collaboration

18. Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia

no benefit in cognitive performance included: vitamin E in women; B 12 plus folic acid for executive/attention/processing speed; and angiotensin-converting enzyme plus thiazide versus placebo and angiotensin receptor blockers versus placebo on brief cognitive screening tests. We found low-strength evidence that the selective estrogen receptor modulator raloxifene reduced risk of probable MCI, but also that estrogen replacement with or without progesterone therapy increased risk of MCI and CATD. Physical (...) 6.1. Summary of results chapters key messages 205 Figures Figure 1.1. Analytic framework for interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer’s-type dementia 9 Figure 3.1. Literature flow diagram 16 Figure 5.1. Summary: Dementia or MCI incidence by intervention type 194 Figure 5.2. Summary of the tests of cognitive performance: results of ACTIVE trial 196 Figure 5.3. Summary of the tests of cognitive performance from additional cognitive training trials

2017 Effective Health Care Program (AHRQ)

19. Interventions to Prevent Age-Related Cognitive Decline, Mild Cognitive Impairment, and Clinical Alzheimer's-Type Dementia

no benefit in cognitive performance included: vitamin E in women; B 12 plus folic acid for executive/attention/processing speed; and angiotensin-converting enzyme plus thiazide versus placebo and angiotensin receptor blockers versus placebo on brief cognitive screening tests. We found low-strength evidence that the selective estrogen receptor modulator raloxifene reduced risk of probable MCI, but also that estrogen replacement with or without progesterone therapy increased risk of MCI and CATD. Physical (...) 6.1. Summary of results chapters key messages 205 Figures Figure 1.1. Analytic framework for interventions to prevent cognitive decline, mild cognitive impairment, and clinical Alzheimer’s-type dementia 9 Figure 3.1. Literature flow diagram 16 Figure 5.1. Summary: Dementia or MCI incidence by intervention type 194 Figure 5.2. Summary of the tests of cognitive performance: results of ACTIVE trial 196 Figure 5.3. Summary of the tests of cognitive performance from additional cognitive training trials

2017 Effective Health Care Program (AHRQ)

20. Recommendation on screening adults for asymptomatic thyroid dysfunction in primary care

for women or men between those treated and not treated with levothyroxine for screen-detected hypothyroidism. Cognitive function Low-certainty evidence from 3 RCTs ( n = 759) , , reported on 22 cognitive function outcome analyses, stemming from 20 unique tests (i.e., 2 tests were included in 2 separate RCTs). Only 2 tests (the Composite Cognitive Score and the Speed and Capacity of Language Processing Test) showed statistically significant treatment effects over placebo (Appendix 3, Supplemental Table 1 (...) levels, particularly for milder cases of thyroid dysfunction (mean follow-up 32–60 mo). , Screening is intended to detect thyroid dysfunction in asymptomatic patients in order to prevent adverse consequences of untreated thyroid dysfunction. Screening is done by performing a blood test for TSH. Abnormal levels of TSH are followed up with additional diagnostic testing that often includes blood tests to measure thyroid hormone levels or other tests (e.g., ultrasound) as warranted. An estimated 10

2019 Canadian Task Force on Preventive Health Care

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>